Exogenous GH can affect central nervous system function when given peripherally to animals and as a supplemental therapy to humans. This study tested whether GH crosses the blood-brain barrier (BBB) by a specific transport system and found that both mice and rats have small but significant uptake of GH into the brain without a species difference. Determined by multiple-time regression analysis, the blood-tobrain influx transfer constants of 125 I-labeled rat GH in mice (0.23 ؎ 0.07 l/g⅐min) and rats (0.32 ؎ 0.04 l/g⅐min) were comparable to those of some cytokines of similar size, with a halftime disappearance of 125 I-GH of 3.8 -7.6 min in blood. Intact 125 I-GH was present in both serum and brain homogenate 20 min after iv injection. At this time, about 26.8% of GH in brain entered the parenchyma, whereas 10% was entrapped in endothelial cells. Neither excess GH nor insulin showed acute modulation of the influx, indicating lack of a saturable transport system for GH at the BBB. T HE PRINCIPAL FORM of GH is a large polypeptide of 191 amino acids (22 kDa). By existing dogma, it would be considered too large a protein to cross the blood-brain barrier (BBB), the communicating interface between the cerebral microcirculation (the periphery) and central nervous system (CNS) parenchyma. Among many restrictive factors, the presence of tight junctions between the capillary endothelial cells composing the BBB and the underlying continuous basement membrane substantially reduces paracellular permeation of large proteins. However, specific transport systems at the BBB have been identified for many peptides and proteins. This growing list includes some ILs (1-4), tumor necrosis factor ␣ (5, 6), and other cytokines that are even larger than GH (7).
T HE PRINCIPAL FORM of GH is a large polypeptide of
191 amino acids (22 kDa) . By existing dogma, it would be considered too large a protein to cross the blood-brain barrier (BBB), the communicating interface between the cerebral microcirculation (the periphery) and central nervous system (CNS) parenchyma. Among many restrictive factors, the presence of tight junctions between the capillary endothelial cells composing the BBB and the underlying continuous basement membrane substantially reduces paracellular permeation of large proteins. However, specific transport systems at the BBB have been identified for many peptides and proteins. This growing list includes some ILs (1-4), tumor necrosis factor ␣ (5, 6), and other cytokines that are even larger than GH (7) .
The speculation that GH crosses the BBB comes from several lines of evidence. First, there are studies showing that exogenous GH used as a supplementary therapy can improve human cognitive function, mood, memory, and sleep (8, 9) . Second, not only can GH affect cerebrospinal fluid (CSF) levels of various neuropeptides, amino acids, and monoamine metabolites (10, 11) , but it also can be recovered from the CSF after peripheral administration (12) . Third, GH receptors are present in the CNS (13) . Recently, the distribution of mRNA for the GH receptor was mapped in rat brainstem and spinal cord (14) . GH also can cause age-dependent up-regulation of its own receptor and change Nmethyl-d-aspartate receptor subunit gene transcripts in the hippocampus (15) . Thus, it is possible that GH penetrates the BBB to exert its effects directly upon the brain. If so, a saturable transport system for GH would be more likely than the process of simple diffusion to be subject to regulation in pathophysiological states, thereby providing a target for therapeutic intervention.
The many CNS effects of GH provide a good reason to determine its mechanism of passage across the BBB. In addition to its effects on cognitive function, mood, memory, and sleep in humans (8, 9) , GH also can exert neuroprotective actions in animal models of spinal cord injury (16, 17) , and hypoxic ischemia (18) . After spinal cord injury in the rat by thoracic dorsal horn incision, there is an age-dependent increase in trauma-induced permeability to GH (19) . If the increased entry of GH to the injured spinal cord is beneficial for neuroregeneration, delivery of therapeutic doses of GH by way of its transport system could further facilitate locomotor recovery.
In addition, GH alters appetite and feeding behavior (20) . It is not known whether these effects occur outside or within the BBB, and if inside, whether by direct action or indirect alteration of other neurotransmitters in response to GH. Thus, a better understanding of the interactions of GH with the BBB could assist in the design of strategies to control feeding.
Despite considerable indirect evidence suggesting that GH may cross the BBB, the possible penetration of GH into the CNS has not been established by pharmacokinetic quantification. In this study, we determined the pharmacokinetics of BBB permeation of radioactively labeled GH by use of multiple-time regression analysis (21) designed to assess the influx transfer of slowly penetrating substances across the BBB. We found that GH had significant entry from blood to brain while remaining intact, and that significantly more of the injected GH entered brain parenchyma than was associated with the cerebral vasculature. However, the entry of GH was not mediated by a saturable transport system. The effects of protamine and poly-l-lysine to increase the internalization of GH by RBE4 cells suggest that heparin sulfate proteoglycan is involved in the interactions between GH and the BBB. Thus, simple diffusion of GH across the BBB provides an explanation of the dose-dependent effect of peripheral GH on CNS function.
Materials and Methods
Adult male CD1 mice of 5-6 wk of age were used following the protocol approved by the Institutional Animal Care and Use Committee. The mice were studied after anesthesia induced by ip injection of ketamine. Recombinant human and rat nonglycosylated GH were obtained from Diagnostic Systems Laboratories (Webster, TX). Recombinant human insulin, BSA, and chloramine-T radiolabeling reagents were purchased from Sigma (St. Louis, MO). GH was radioactively labeled with 125 I by the chloramine-T method with the reaction stopped at 1 min by addition of sodium metabisulfate and purified on Sephadex G-10. The specific activity of 125 I-GH was about 200 Ci/g. Albumin was radioactively labeled with 131 I by the chloramine-T method with a specific activity of about 60 Ci/g. Most studies involved rat 125 I-GH in mice unless otherwise specified.
Multiple-time regression analyses
To determine whether rat GH enters the mouse brain and whether it does so by saturable transport, two groups of mice were studied: one with radioactively labeled compounds only and a similar group with inclusion of 1 g/mouse of unlabeled GH. The injection solution of lactated Ringer's with 1% BSA (LR/BSA) was prepared fresh each time. There were seven mice in each group. A mixture of 30,000 cpm/l each of 125 I-GH and 131 I-albumin in 100 l of injectate was delivered to the left jugular vein at time 0. At various times between 1 and 30 min, blood was collected from a cut in the right common carotid artery and the mouse was decapitated immediately afterwards. The radioactivity in the whole brain and 50 l of serum was measured, and the brain/serum ratio of 125 I-GH and 131 I-albumin in each gram of brain was calculated separately. Based on the exponential decay pattern of serum radioactivity, the exposure time was calculated for each time point. The exposure time is the integral of serum radioactivity over time divided by the serum radioactivity at a given time (21) . The linear regression correlation between the brain/serum ratio and exposure time was determined by use of GraphPad Statistical Software (GraphPad, San Diego, CA). The unidirectional influx transfer constant (Ki) was determined from the slope of the linear regression line, and the initial volume of distribution (Vi) was determined from the intercept. Differences of the regression lines between the two groups were compared by the least square method by use of the GraphPad program.
To determine the dose of excess unlabeled GH required for potential saturation, the experiment was repeated with higher doses of GH. To test the species specificity of BBB permeation, human and rat 125 I-GH were used separately in the studies on mice, and rat 125 I-GH was used in both young male CD1 mice and Wistar rats.
In addition to multiple-time regression analyses, single-time uptake of 125 I-GH was determined at 10 min after iv injection in mice and the potential modulatory effect of excess GH and insulin was determined by one-way ANOVA (n ϭ 6/group).
Degradation assays by HPLC, acid precipitation, and gel autoradiography
Each mouse received an iv injection of 3-4 Ci of 125 I-GH in 100 l of injection at time 0. At 20 min, arterial blood and brain were obtained and processed on ice. The brain was homogenized in 1 ml of LR/BSA in the presence of Complete Protease Inhibitor Cocktail (Sigma). To assess the extent of ex vivo degradation, a processing control was generated by addition of 125 I-GH into the blood-collection tube and brain homogenate. About 30,000 cpm of brain supernatant or serum was injected onto the reversed phase HPLC or precipitated by 15% of trichloroacetic acid. The mobile phase of HPLC was acetonitrile with 0.1% trifluoroacetic acid that was increased from 10 -100% over 40 min.
For gel autoradiography, protein from the serum and brain homogenate was fractionated with 8% SDS-PAGE. There were five groups: serum and brain samples of the processing control and mice receiving 125 I-GH iv, and the stock solution. The proteins were transferred to a nitrocellulose membrane, and exposed to x-ray film at Ϫ80 C.
In situ brain perfusion
The composition of the perfusion buffer and the conditions for perfusion have been described previously (22) . In brief, a group of eight to 10 mice that received 125 I-GH and 131 I-albumin was studied in parallel with a group that received additional unlabeled GH at 20 g/ml. After clamping of the abdominal aorta and severing of the jugular veins of the anesthetized mice, the oxygenated perfusate was delivered at 2 ml/min for various time intervals between 1 and 10 min. The perfusion buffer contained about 2000 cpm/l of 125 I-GH and 131 I-albumin. Each mouse received a prewash of 2 min to clear the cerebral vasculature and 1 min of postwash to remove radioisotopes that had not entered the brain. At the end of the procedure at each time point, the mouse was decapitated, and the brain/perfusate ratio of radioactivity per gram of brain was measured. Statistical analysis was performed as above.
Capillary depletion
Four groups of mice (n ϭ 4/group) were studied. The groups were mice receiving 125 I-GH and 131 I-albumin with or without cardiac perfusion to wash out residual radioactivity in the cerebral vasculature, and mice receiving additional excess GH at 10 g/mouse with or without cardiac perfusion with 20 ml of LR. At the end of the study (10 min after iv injection), blood and brain were collected. The cerebral cortex was homogenized in capillary buffer (22) and mixed thoroughly with dextran to yield a final concentration of dextran of about 18.4%. The mixture was centrifuged at 9000 ϫ g for 30 min at 4 C with a swing bucket rotor to achieve effective separation of brain parenchyma from the capillaries. After measurement in a ␥-counter, the ratios of tissue/serum radioactivity for 125 I-GH and 131 I-albumin were calculated and expressed per gram of cerebral cortex. Group means are presented with their ses, statistically significant differences being determined by ANOVA followed by Tukey's post hoc test.
Cellular uptake assays
The control group with 125 I-GH only was studied simultaneously (triplicated wells/group) with the following potential modulators: excess unlabeled GH (1 mg/ml), 500 mm monodansylcadeverine (an inhibitor of adsorptive endocytosis), 300 mm protamine, 300 mm poly-llysine (both being positively charged proteins that also inhibit adsorptive endocytosis), and hypertonic sucrose (1.2 m). Equal numbers of immortalized rat brain microvessel endothelial cells RBE4 (kind gift from NeuroTech, Paris, France) were seeded to six-well plates precoated with rat tail collagen. Radiotracer uptake assays were performed when the cells grew confluent. The cells were preequilibrated for 15 min in 1 ml of transport buffer that contained equal amounts of ␣MEM and F10, supplemented with 20 mm HEPES and 0.05% BSA.
125 I-GH (700,000 cpm/ml) was added in 1 ml of transport buffer prewarmed to 37 C, and the plates were gently agitated for 20 min. At this time, internalization of 125 I-GH was terminated by transferring the plates to ice, followed by rapid removal of the transport buffer and three washes with ice-cold PBS. Afterwards, specific cell surface binding was determined by incubation of the cells with ice-cold stop-strip buffer [0.2 n acetic acid in PBS (pH 2.5)] for 10 min and collection of this and subsequent washes with stop-strip buffer. The cells were then lysed and collected. The maximal potential internalization represents the amount of radioactivity from the acid-resistant binding combined with the amount internalized at the same time point. The percent of surface binding and maximal potential internalization were determined by normalization of the values of individual wells to the total amount of 125 I-GH added at time 0.
Separate groups were studied at 0 C to inhibit endocytosis and compared with groups studied at 37 C. For the 0 C groups, the plates were kept on ice the entire time. Group means were expressed with their ses, and statistically significant changes were determined by an overall ANOVA for each fraction, followed by Tukey's post hoc test.
In contrast to continuous uptake of 125 I-GH for 20 min, the radiotracer pulse-chasing study was performed to determine the internalization at 20 min after binding equilibrium. The control group with 125 I-GH only was studied simultaneously with the following five groups: 1 mg/ml of unlabeled GH, 300 mm of protamine, both protamine and unlabeled GH, 50 g/ml of heparin, and 300 mm of poly-l-lysine. After equilibration of cells in ice-cold transport buffer for 15 min, the cells were incubated in ice-cold transport buffer containing 125 I-GH with or without the above potential modulators (700,000 cpm/ml) at 4 C for 1 h. Afterwards the radioactively labeled tracer was removed by two washes with ice-cold PBS, and the plates were rapidly warmed up to 37 C in the presence of prewarmed transport buffer. At 20 min, surface binding and maximal potential internalization were determined as above.
Results

Influx transfer of 125 I-GH from blood to brain
The blood-to-brain influx of 125 I-GH was linear during the study period (1-30 min after iv injection in mice). As shown in Fig. 1A , the influx transfer constant was 0.23 Ϯ 0.07 l/ g⅐min and the initial volume of distribution was 15.5 l/g. Of the total amount injected iv, the percent of brain uptake was about 0.1%/gram of brain at 20 min. Given the specific activity of 200 Ci/g of 125 I-GH and the injection amount of 1.36 Ci, about 6.8 pg of GH was present in a gram of brain tissue. The results indicated that a significant amount of 125 I-GH reached the brain, and this was supported by results from degradation studies showing that most of the measured radioactivity represented intact GH (see below). Addition of 1 g/mouse of unlabeled GH (about 150-fold excess) to the 125 I-GH injection solution did not significantly affect the rate of entry. The lack of inhibitory effect of unlabeled GH was reproduced in subsequent experiments with various doses of GH and shorter time intervals. The serum half-life of 125 I-GH ranged from 3.8 -7.6 min in different experiments.
To further determine the possible presence of a saturable transport system as well as modulation by insulin, which affects GH, three groups of mice were studied (n ϭ 6/group). At 10 min after iv injection of 125 I-GH, the volume of distribution of 125 I-GH in the brain was 14.80 Ϯ 0.80 l/g. It was not significantly changed by the addition of 200 g/mouse (about 30,000-fold excess) of unlabeled GH (Vi ϭ 15.50 Ϯ 0.95 l/g) or 10 g/mouse of unlabeled insulin (Vi ϭ 14.20 Ϯ 0.22 l/g). This is shown in Fig. 1B . Similarly, the influx transfer constant of 125 I-insulin, which was 0.97 Ϯ 0.14 l/g⅐min, was not significantly changed by the presence of 10 g/mouse of unlabeled GH (Ki ϭ 0.71 Ϯ 0.18 l/g⅐min).
A further study was performed with radioactively labeled rat GH injected iv into rats. The influx transfer constant to the whole brain was 0.32 Ϯ 0.04 l/g⅐min, and the initial volume of distribution was 19.27 Ϯ 0.74 l/g. Addition of 80 g/rat of excess unlabeled GH did not cause a significant change in the influx rate [F (1, 19) ϭ 0.6, P Ͼ 0.05] (Fig. 1C) . There was no significant regional difference in the influx transfer constant of 125 I-GH among the dissected brain regions (frontal, parietal, occipital cortices, striatum, thalamus, hypothalamus, brainstem, and cerebellum). In each region, there was There were no significant differences among the groups. C, Influx of rat 125 I-GH in rats was slightly faster (Ki ϭ 0.32 Ϯ 0.04 l/g⅐min) than that in mice; however this was not saturable. no significant effect of excess unlabeled GH that would have indicated saturable transport.
Degradation assays to determine that the radioactivity measured represented intact 125 I-GH
After 20 min of iv circulation, HPLC showed that intact 125 I-GH accounted for 91% of the total radioactivity in serum, similar to that in the serum of the processing control in which 125 I-GH was mixed with blood in the test tube only. In serum samples, up to 90% in mouse 20 min after iv injection of 125 I-GH and 95% of radioactivity in the processing control were acid precipitable. In the supernatant of brain homogenate, up to 81% in mouse 20 min after iv injection of 125 I-GH and 94% in the processing control were also acid precipitable. Similarly, the radioactivity in the brain after 10 min of in situ brain perfusion mainly represented intact 125 I-GH. The acid precipitable radioactivity was 90% in brain after 10 min of in situ perfusion of 125 I-GH, and 89.4% in brain after perfusion of 125 I-GH along with excess unlabeled GH. The results indicate that intact 125 I-GH was present in the brain after iv delivery. This is further supported by the presence of a radioactive band at molecular mass of 22 kDa in gel autoradiography in all samples, correlating with intact 125 I-GH.
In situ brain perfusion studies to determine the transfer of 125 I-GH across the BBB
To eliminate the possibility that serum GH binding proteins interfered with detection of a saturable transport system, and to confirm that the radioactivity measured in the whole brain of mice after iv injection of 125 I-GH had reached the brain compartment rather than remaining in the vasculature, in situ brain perfusion was performed with serum-free buffer. The control group received 125 I-GH and 131 I-albumin whereas the experimental group received 20 g/ml of unlabeled GH in addition. The influx transfer constant of 125 I-GH was 0.84 Ϯ 0.08 l/g⅐min without excess GH and 0.82 Ϯ 0.10 l/g⅐min in the presence of excess GH; there was no significant difference between the two groups (Fig. 2) . Therefore, the lack of saturation was not explained by the presence of serum binding proteins. This further supports the conclusion that the substantial entry of rat GH across the mouse BBB did not occur by a saturable transport system.
Differentiation of the amount of 125 I-GH taken up by the brain vs. that trapped in the cerebral vasculature
As shown in Fig. 3 , the nonperfused brain had an apparently high volume of distribution of 125 I-GH when the brain was obtained 10 min after iv injection (n ϭ 4 /group). This reflects high uptake in the brain parenchymal fraction (12.60 Ϯ 0.61 l/g) and low uptake in the capillary fraction (3.63 Ϯ 0.76 l/g). However, the vascular marker 131 I-albumin had a parenchymal uptake of 6.77 Ϯ 0.50 l/g and capillary uptake of 0.75 Ϯ 0.08 l/g. These values roughly represent the radioactivity that is either in the capillary lumen or loosely bound to the capillary walls because albumin is considered to have minimal transcellular permeation of an intact BBB. Thus, the actual uptake of 125 I-GH into the brain parenchyma, as shown after perfusion to wash out the vascular space, was only 4.35 Ϯ 0.32 l/g, or 26.8% of the total radioactivity measured in the whole brain. The actual amount of 125 I-GH trapped in the cerebral vasculature was 1.63 Ϯ 0.39 l/g at 10 min, or 10% of the total radioactivity. This is significantly less than that reaching the brain paren-
Uptake of 125 I-GH by RBE4 cells and its modulation by protamine and poly-L-lysine
The concentration of 125 I-GH in the transport buffer (700,000 cpm/ml, with specific activity of 200 Ci/g) was about 1.6 ng/ml. Therefore, 1 mg/ml of excess unlabeled GH represented over 60,000 times excess. At this dose, there was no significant inhibition of either surface binding or internalization of 125 I-GH. Thus, there was no saturable transport system for GH in the cultured RBE4 cells. To further rule out adsorptive endocytosis, which can occur with glycoproteins and has a lower affinity and higher capacity than receptormediated endocytosis, specific inhibitors for adsorptive endocytosis (monodansylcadeverine, poly-l-lysine, and protamine)were also included in the study. Monodansylcadeverine had no significant effect on surface binding or internalization of 125 I-GH after 20 min of coincubation. Unexpectedly, the percent of 125 I-GH at the cell surface at 20 min was significantly increased in the presence of protamine (P Ͻ 0.05), whereas that internalized was also significantly increased by both protamine and poly-l-lysine (P Ͻ 0.01). Hypertonic buffer significantly decreased (P Ͻ 0.05) surface binding without affecting maximal potential internalization. Both binding and internalization were significantly decreased in low temperature at this time (P Ͻ 0.01). The lack of inhibitory effects of protamine, poly-l-lysine, and monodansylcadeverine ruled out the possibility of adsorptive endocytosis (Fig. 4A) .
The significantly less binding of 125 I-GH at 4 C in contrast to that at 37 C suggests that binding equilibrium had not been achieved during the incubation period. Thus, a further study was performed by pulse-chasing, in which the cells were incubated with 125 I-GH at 4 C for 1 h and then internalization of the bound 125 I-GH at 20 min was determined. Similar to what was seen in Fig. 4A , the surface binding and internalization were both significantly increased by protamine (P Ͻ 0.01). This increase was not affected by addition of excess unlabeled GH. In contrast, poly-l-lysine and heparin showed no significant effects (Fig. 4B ).
Discussion
It is well known that GH in the peripheral circulation can exert multiple CNS effects. The recovery of GH in the CSF (12) suggested that GH crosses the BBB. Here we provide the first direct evidence that recombinant, nonglycosylated human and rat GH could be stable enough in the blood and cerebral microcirculation to permeate the BBB of mouse and rat. With a sensitive radiotracer uptake method, we showed that the polypeptide GH had an influx transfer constant of 0.23 Ϯ 0.07 l/g⅐min in mice and 0.32 Ϯ 0.04 l/g⅐min in rats, a value comparable to that of some neurotropins and cytokines, polypeptides known to cross the BBB (7, (22) (23) (24) (25) . HPLC, acid precipitation, and gel autoradiography confirmed that the radioactivity measured in the brain was mainly intact 125 I-GH rather than products of degradation.
GH had a moderately high initial volume of distribution in the brain. The majority of the peripherally injected 125 I-GH was retained in the cerebral vasculature 10 min after iv injection, although a significant amount (26.8%) entered brain parenchyma, whereas 10% was retained in the microvessel endothelial cells composing the BBB. Consistent with the capillary depletion studies, in situ brain perfusion showed that the perfusate-to-brain transfer of 125 I-GH was about 35 times lower than that of nerve growth factor (22) and about 250 times lower than that of brain-derived neurotrophic factor (26) . Similar to what we have seen for other proteins, the primary structure or the presence of receptors may not be the determining factor for BBB permeability. Regardless, a significant amount of GH can cross the BBB to exert CNS effects directly.
The permeation of GH, however, is a nonsaturable process, as shown both in vivo and in vitro. In studies with cultured cerebral microvessel endothelial cells (major components of the BBB), surface binding of 125 I-GH did not seem to be mediated by specific GH receptors because excess unlabeled GH failed to inhibit the binding or internalization of 125 I-GH. Although it is possible that glycosylated GH might be internalized by adsorptive endocytosis, modulators of adsorptive endocytosis (dansylcadeverine, protamine, and poly-l-lysine) failed to decrease the uptake of nonglycosylated GH in this study, thus ruling out the presence of adsorptive endocytosis (27) for this commonly used form of the hormone. The enhancing effect of protamine might be explained by its binding to GH, thereby increasing its positive charge so as to facilitate adsorptive endocytosis, as it does for albumin (28) . However, adsorptive endocytosis is usually a specific process, but the uptake of 125 I-GH was not saturable by coadministration of excess unlabeled GH. Nonetheless, naturally occurring GH may be glycosylated, which increases its chance of adsorptive endocytosis. Endogenous GH can exist in different forms due to posttranslational modifications, including deamidation, acylation, glycosylation, and oligomerization, thereby resulting in distinct kinetic patterns of clearance, receptor binding, and complexing with binding proteins (29) . Although there do not seem to be major differences in biological activity among these forms (30), it is possible that different forms of GH penetrate the BBB in different ways.
The plasma concentration of GH has a distinctive circadian rhythm and ranges from 0 -250 ng/ml. Therefore, although the trace amount of I-GH would not increase the blood level of GH, the excess exogenous GH injected to test for saturation might affect the concentration of GH and the subsequent mediators of its function. This could be an issue for long-term effects in survival studies. Nonetheless, it should not affect the conclusions from the acute in vivo studies.
Based on the lack of inhibition by a large excess of GH in the in vivo and in vitro experiments, we conclude that it is unlikely the GH receptor or other carrier systems are involved in the blood-to-brain transfer of GH. This means that the permeation of GH probably occurs by the process of simple diffusion dependent on the physiochemical properties of GH. In pathological conditions in which the BBB is partially disrupted, such as CNS trauma, hypoxia/ ischemia, tumor, and certain developmental or degenerative stages, more GH could reach its brain targets than by a process limited by saturation. The permeation of peripheral GH across the BBB does not override the importance of neuronal sources of GH, such as in the hypothalamic region of rats (31) and retina of embryonic chicks (32) , which play important roles in neuromodulation.
It has been suggested that peripheral GH can be detected in the brain and CSF; however, there has not been direct demonstration whether and how the BBB is involved. Because the choroid plexus has a high level of expression of GH receptors, receptor-mediated transport is possible there. Despite the theoretical possibility that the blood-CSF barrier may possess a specific transport system, our pharmacokinetic study on mice and rats ruled out receptor-mediated transport for GH at the BBB. Results from cultured cerebral microvessel endothelial cells also ruled out high-capacity adsorptive endocytosis. Despite the lack of a specific transport system, GH was relatively stable in blood within the first 10 min after iv delivery and underwent limited simple diffusion across the BBB. The   FIG. 4 . A, Binding and endocytosis of 125 I-GH in cerebral endothelial RBE4 cells 20 min after incubation at 37 C for 20 min. The binding and endocytosis were both significantly enhanced by protamine and decreased at low temperature. The binding was also significantly increased by poly-L-lysine, whereas the adsorptive endocytosis inhibitor monodansylcaverine had no effect. *, P Ͻ 0.05; ***, P Ͻ 0.005. B, Binding of 125 I-GH at 4 C and internalization (37 C for 20 min) were significantly increased by protamine although the process was still not saturable (excess GH had no additional effect). *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.005; NS, not significantly different. majority of GH entering the cerebral circulation was retained in the cerebral vasculature, but significant penetration to brain parenchyma did occur. These studies add definitive value to the long dispute whether and how GH crosses the BBB.
